Gene therapy injection aims to lower eye pressure in glaucoma
NCT ID NCT06921317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new gene therapy called GVB-2001 for people with primary open-angle glaucoma. The treatment is given as an injection into the eye to help lower high pressure inside the eye. About 6 adults aged 18 to 75 with glaucoma for at least a year will take part. The main goals are to check if the treatment is safe and if it can reduce eye pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily reading drill restore lost reading skills in glaucoma?
- New surgical tool aims to lower eye pressure in glaucoma patients
- Could removing preservatives from glaucoma drops save Patients' eyes?
- New eye drug targets fluid buildup to fight glaucoma
- New Preservative-Free eye drop could match leading glaucoma treatment
- Texting your way to better glaucoma care: new trial tests daily reminders